Compared to controls, the Erlotinib-treated eNOS deficient db/db mice had markedly decreased albuminuria, glomerulosclerosis, podocyte loss, and fibrosis (Li et al., 2018a). The gene discussed is NOS3; the disease is glomerulosclerosis.